Answers are grounded in this paper and cite their sources.
Retrospective study examines treatment patterns in advanced non-small cell lung cancer with NGS results, indicating significant gaps in guideline-recommended care.
• Roughly 30% of patients with biomarker-positive disease did not receive the indicated 1L guideline-recommended targeted therapy despite availability of NGS test results prior to 1L initiation • Patients treated with 1L targeted therapy had the longest median overall survival • EHR-based alerts could help increase the uptake of biomarker-driven treatment • There is an unmet need for 1L treatment in a/mNSCLC, particularly for KRAS G12C & HER2 This study examined treatment patterns among patients with available next generation sequencing (NGS) results before starting first-line (1L) treatment, using either tissue-based (T-NGS) or blood-based (B-NGS) NGS testing in patients with advanced/metastatic non-small cell lung cancer (a/mNSCLC). This retrospective study included US patients aged ≥18 years with a/mNSCLC who received a T-NGS or B-NGS test and had results available prior to 1L. Most frequent (n≥40) treatment patterns were reported as sequence of treatments received in 1L through (→) second line (2L). Overall survival (OS) was measured from the date of NGS test result. Descriptive analyses were conducted separately in T-NGS and B-NGS, stratified by biomarker status. A total of 2980 (T-NGS, 1632; B-NGS, 1348) patients were eligible. The median age was 71 years, 52% female, 62% White, and 83% smokers. Approximately 32% (T-NGS, 35%; B-NGS, 32%) of patients were positive for biomarkers and receipt of targeted therapy (TT) in 1L was ≤68% (T-NGS, 67%; B-NGS, 70%). Median OS was longest for ‘TT → none’ in the biomarker-positive subgroups of both cohorts. Approximately 30% of patients with biomarker-positive disease did not receive the indicated 1L guideline-recommended TT despite availability of NGS test results prior to 1L initiation. These findings highlight variability in 1L treatment selection for patients with biomarker-positive a/mNSCLC and underscore the need for further research to understand barriers to TT use. Health systems should consider proactive, scalable solutions (e.g., EHR-based alerts) to ensure that biomarker-driven treatment is not just possible but reliably delivered.
No takes yet. Share an insight, caveat, or question.
Marmarelis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: